Sugi Predict

Sugi Predict / Compounds / SCHEMBL4460715

SCHEMBL4460715

SCHEMBL4460715

Cc1cc(N)ccc1Oc1cccc(C(=O)OC(C)(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 1/20 0.43
▸ PGR P06401 1/20 0.40
▸ AR P10275 1/20 0.40
▸ GCK P35557 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ MRGPRX4 Q96LA9 1/20 0.38
▸ F10 P00742 2/20 0.37
▸ TNKS O95271 1/20 0.37
▸ PARP15 Q460N3 1/20 0.37
▸ PARP14 Q460N5 1/20 0.37
▸ PARP10 Q53GL7 1/20 0.37
▸ TNKS2 Q9H2K2 1/20 0.37
▸ PARP2 Q9UGN5 1/20 0.37
▸ STAT3 P40763 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4466049 0.86 CA12 (0.42) USP2HPGDPARP10STAT3BRD4
SCHEMBL3510178 0.81 ALDH1A1 (0.48) PGRARGCKF10CYP1A2
SCHEMBL4466094 0.81 ALDH1A1 (0.50) MAPTLMNAPOLB
SCHEMBL14966928 0.80 TTR (0.48) SLC7A5PGRARBRD4MAPT
SCHEMBL29972954 0.79 USP2 (0.55) SLC7A5USP2HPGDTNKSPARP15
SCHEMBL381125 0.78 SLC7A5 (0.55) SLC7A5STAT3NPC1MITFLMNA
SCHEMBL29634161 0.78 SLC7A5 (0.55) SLC7A5STAT3NPC1MITFLMNA
SCHEMBL2997554 0.78 ALDH1A1 (0.53) MAPTMITFLMNAPOLB
SCHEMBL7569937 0.76 MAOB (0.55) MAPTMITFPOLB
SCHEMBL25736538 0.74 AKR1C3 (0.46) SLC7A5TNKSPARP15PARP14PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585869-B2 Substituted heterocylces for the treatment of abnormal cell growth PFIZER, INC. (US) 2009-09-08 — — US disclosed
US-7585869-B2 Substituted heterocylces for the treatment of abnormal cell growth PFIZER, INC. (US) 2009-09-08 — — US disclosed
US-7585869-B2 Substituted heterocylces for the treatment of abnormal cell growth PFIZER, INC. (US) 2009-09-08 — — US disclosed
EP-1636195-A1 QUINAZOLINES AND PYRIDO[3,4-D]PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS Pfizer Products Inc. (US) 2006-03-22 — — EP disclosed
WO-2004106308-A1 QUINAZOLINES AND PYRIDO [3,4-D] PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2004-12-09 — — WO disclosed
US-20040242604-A1 Substituted heterocycles for the treatment of abnormal cell growth PFIZER INC 2004-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242604-A1 Substituted heterocycles for the treatment of abnormal cell growth CCNA1, CCNT1, CCNY SLC7A5 853/4885PGR 824/4885AR 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.